Literature DB >> 26392488

Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.

I J Abbott1, A W J Jenney2, C J Jeremiah2, M Mirčeta2, J P Kandiah3, D C Holt3, S Y C Tong3, D W Spelman2.   

Abstract

A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, >1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P < 0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26392488      PMCID： PMC4649159          DOI： 10.1128/AAC.02015-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  38 in total

1.  Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Dorothy James; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2015-08-27       Impact factor: 5.790

2.  Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia.

Authors:  Nasmiya Mubarak; Indy Sandaradura; Lupeoletalalelei Isaia; Matthew O'Sullivan; Fei Zhou; Deborah Marriott; Jon R Iredell; John Harkness; David Andresen
Journal:  J Antimicrob Chemother       Date:  2015-05-14       Impact factor: 5.790

3.  Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.

Authors:  Sushmita D Lahiri; Robert E McLaughlin; James D Whiteaker; Jane E Ambler; Richard A Alm
Journal:  J Antimicrob Chemother       Date:  2015-06-04       Impact factor: 5.790

4.  In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus isolates.

Authors:  S Basireddy; M Singh; S Ali; V Kabra
Journal:  Indian J Med Microbiol       Date:  2015 Jul-Sep       Impact factor: 0.985

5.  Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).

Authors:  Helio S Sader; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2015-03-25       Impact factor: 5.790

6.  Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Dorothy James; Angela Kearns; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2015-07-04       Impact factor: 5.790

7.  Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.

Authors:  Helio S Sader; David J Farrell; Rodrigo E Mendes; Robert K Flamm; Mariana Castanheira; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2015-02-10       Impact factor: 2.803

8.  Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study.

Authors:  C Leprince; M Desroches; A Emirian; C Coutureau; L Anais; V Fihman; C J Soussy; J W Decousser
Journal:  Diagn Microbiol Infect Dis       Date:  2015-06-17       Impact factor: 2.803

9.  Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.

Authors:  Liana C Chan; Li Basuino; Binh Diep; Stephanie Hamilton; Som S Chatterjee; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

10.  The utility of high-resolution melting analysis of SNP nucleated PCR amplicons--an MLST based Staphylococcus aureus typing scheme.

Authors:  Rachael A Lilliebridge; Steven Y C Tong; Philip M Giffard; Deborah C Holt
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240
View more
  5 in total

Review 1.  Antimicrobial resistance in methicillin-resistant Staphylococcus aureus to newer antimicrobial agents.

Authors:  Richard R Watkins; Marisa Holubar; Michael Z David
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

Review 2.  Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Isaac Yin Sum Mok; Andrew Song; Drosos E Karageorgopoulos; Apostolos Armaganidis; Jeffrey Lipman; Sotirios Tsiodras
Journal:  Microorganisms       Date:  2019-08-18

3.  Using genomics to understand meticillin- and vancomycin-resistant Staphylococcus aureus infections.

Authors:  Stefano G Giulieri; Steven Y C Tong; Deborah A Williamson
Journal:  Microb Genom       Date:  2020-01

4.  Evaluation of in vitro activity of ceftaroline on methicillin resistant Staphylococcus aureus blood isolates from Iran.

Authors:  Negin Abdizadeh; Mehri Haeili; Hossein Samadi Kafil; Amin Ahmadi; Mohammad Mehdi Feizabadi
Journal:  Iran J Microbiol       Date:  2021-08

5.  CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.

Authors:  Steven Y C Tong; Jane Nelson; David L Paterson; Vance G Fowler; Benjamin P Howden; Allen C Cheng; Mark Chatfield; Jeffrey Lipman; Sebastian Van Hal; Matthew O'Sullivan; James O Robinson; Dafna Yahav; David Lye; Joshua S Davis
Journal:  Trials       Date:  2016-03-31       Impact factor: 2.279
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.